Get Informed About the WATCHMANTM Implant Procedure
What is the recommended post-implant regime for my patient?
Post-implant medication is at the discretion of each physician and is subject to the patient's specific condition and medical history. Boston Scientific does provide general guidelines in the instructions for use (IFU) of the device. These have been updated based on the robust clinical results observed in the EWOLUTION registry. With the new recommendations, patients for whom there is no specific medical need for continued use of aspirin could be taken of the drug after a minimum period of 12 months. In addition, depending on patient preference, risk of bleeding and stroke risk, clopidogrel and/or any NOAC or OAC should be prescribed for at least 3 months following the procedure. For additional information, please contact your implanting centre.
* Implant success defined as deployment and release of the device into the LAA; no leak ≥ 5 mm
1. Boersma LVA et al. Implant Success and Safety of Left device: periprocedural outcomes from the EWOLUTION Registry. Eur Heart J 2016;37(31):2465-74.
2. INTERIM POST-MARKET SURVEILLANCE STUDY REPORT on EWOLUTION May 5, 2017
CAUTION: The law restricts these devices to sale by our on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.
Information for the use only in countries with applicable health authority product registrations. Information contained herein is for distribution outside the U.S., Japan and France.